Neutralization breadth of SARS-CoV-2 viral variants following primary series and booster SARS-CoV-2 vaccines in patients with cancer
Copyright © 2021 Elsevier Inc. All rights reserved..
Patients with cancer are more likely to have impaired immune responses to SARS-CoV-2 vaccines. We study the breadth of responses against SARS-CoV-2 variants after primary vaccination in 178 patients with a variety of tumor types and after booster doses in a subset. Neutralization of alpha, beta, gamma, and delta SARS-CoV-2 variants is impaired relative to wildtype, regardless of vaccine type. Regardless of viral variant, mRNA1273 is the most immunogenic, followed by BNT162b2, and then Ad26.COV2.S. Neutralization of more variants (breadth) is associated with a greater magnitude of wildtype neutralization, and increases with time since vaccination; advancing age associates with a lower breadth. The concentrations of anti-spike protein antibody are a good surrogate for breadth (positive predictive value of =90% at >1,000 U/mL). Booster SARS-CoV-2 vaccines confer enhanced breadth. These data suggest that achieving a high antibody titer is desirable to achieve broad neutralization; a single booster dose with the current vaccines increases the breadth of responses against variants.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:40 |
|---|---|
| Enthalten in: |
Cancer cell - 40(2022), 1 vom: 10. Jan., Seite 103-108.e2 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Naranbhai, Vivek [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 19.01.2022 Date Revised 11.01.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.ccell.2021.12.002 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM335259138 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM335259138 | ||
| 003 | DE-627 | ||
| 005 | 20231225225428.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.ccell.2021.12.002 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1117.xml |
| 035 | |a (DE-627)NLM335259138 | ||
| 035 | |a (NLM)34990570 | ||
| 035 | |a (PII)S1535-6108(21)00614-0 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Naranbhai, Vivek |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Neutralization breadth of SARS-CoV-2 viral variants following primary series and booster SARS-CoV-2 vaccines in patients with cancer |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 19.01.2022 | ||
| 500 | |a Date Revised 11.01.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2021 Elsevier Inc. All rights reserved. | ||
| 520 | |a Patients with cancer are more likely to have impaired immune responses to SARS-CoV-2 vaccines. We study the breadth of responses against SARS-CoV-2 variants after primary vaccination in 178 patients with a variety of tumor types and after booster doses in a subset. Neutralization of alpha, beta, gamma, and delta SARS-CoV-2 variants is impaired relative to wildtype, regardless of vaccine type. Regardless of viral variant, mRNA1273 is the most immunogenic, followed by BNT162b2, and then Ad26.COV2.S. Neutralization of more variants (breadth) is associated with a greater magnitude of wildtype neutralization, and increases with time since vaccination; advancing age associates with a lower breadth. The concentrations of anti-spike protein antibody are a good surrogate for breadth (positive predictive value of =90% at >1,000 U/mL). Booster SARS-CoV-2 vaccines confer enhanced breadth. These data suggest that achieving a high antibody titer is desirable to achieve broad neutralization; a single booster dose with the current vaccines increases the breadth of responses against variants | ||
| 650 | 4 | |a Comparative Study | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, N.I.H., Extramural | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Ad26.COV2.S | |
| 650 | 4 | |a BNT162b2 | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a booster dose | |
| 650 | 4 | |a breadth | |
| 650 | 4 | |a cancer | |
| 650 | 4 | |a mRNA1273 | |
| 650 | 4 | |a neutralization | |
| 650 | 4 | |a variants | |
| 650 | 7 | |a Antibodies, Neutralizing |2 NLM | |
| 650 | 7 | |a Antibodies, Viral |2 NLM | |
| 650 | 7 | |a Antigens, Viral |2 NLM | |
| 650 | 7 | |a COVID-19 Vaccines |2 NLM | |
| 650 | 7 | |a Spike Glycoprotein, Coronavirus |2 NLM | |
| 650 | 7 | |a spike protein, SARS-CoV-2 |2 NLM | |
| 700 | 1 | |a St Denis, Kerri J |e verfasserin |4 aut | |
| 700 | 1 | |a Lam, Evan C |e verfasserin |4 aut | |
| 700 | 1 | |a Ofoman, Onosereme |e verfasserin |4 aut | |
| 700 | 1 | |a Garcia-Beltran, Wilfredo F |e verfasserin |4 aut | |
| 700 | 1 | |a Mairena, Cristhian B |e verfasserin |4 aut | |
| 700 | 1 | |a Bhan, Atul K |e verfasserin |4 aut | |
| 700 | 1 | |a Gainor, Justin F |e verfasserin |4 aut | |
| 700 | 1 | |a Balazs, Alejandro B |e verfasserin |4 aut | |
| 700 | 1 | |a Iafrate, A John |e verfasserin |4 aut | |
| 700 | 0 | |a CANVAX team |e verfasserin |4 aut | |
| 700 | 1 | |a Sullivan, Ryan J |e investigator |4 oth | |
| 700 | 1 | |a Bardia, Aditya |e investigator |4 oth | |
| 700 | 1 | |a Spring, Laura M |e investigator |4 oth | |
| 700 | 1 | |a Isakoff, Steven J |e investigator |4 oth | |
| 700 | 1 | |a Farmer, Jocelyn R |e investigator |4 oth | |
| 700 | 1 | |a Zubiri, Leyre |e investigator |4 oth | |
| 700 | 1 | |a Hobbs, Gabriella S |e investigator |4 oth | |
| 700 | 1 | |a How, Joan |e investigator |4 oth | |
| 700 | 1 | |a Brunner, Andrew M |e investigator |4 oth | |
| 700 | 1 | |a Fathi, Amir T |e investigator |4 oth | |
| 700 | 1 | |a Pernat, Clarie A |e investigator |4 oth | |
| 700 | 1 | |a Gavralidis, A |e investigator |4 oth | |
| 700 | 1 | |a Peterson, Jennifer L |e investigator |4 oth | |
| 700 | 1 | |a Sakhi, Mustafa |e investigator |4 oth | |
| 700 | 1 | |a Hambelton, Grace |e investigator |4 oth | |
| 700 | 1 | |a Denault, Elyssa N |e investigator |4 oth | |
| 700 | 1 | |a Mortensen, Lindsey J |e investigator |4 oth | |
| 700 | 1 | |a Periello, Lailoo A |e investigator |4 oth | |
| 700 | 1 | |a Bruno, Marissa N |e investigator |4 oth | |
| 700 | 1 | |a Bruno, M N |e investigator |4 oth | |
| 700 | 1 | |a Betraux, Brittany Y |e investigator |4 oth | |
| 700 | 1 | |a Lawless, Alyssa R |e investigator |4 oth | |
| 700 | 1 | |a Jackson, Melissa A |e investigator |4 oth | |
| 700 | 1 | |a Niehoff, Elizabeth |e investigator |4 oth | |
| 700 | 1 | |a Barabell, Claire |e investigator |4 oth | |
| 700 | 1 | |a Nambu, Christain N |e investigator |4 oth | |
| 700 | 1 | |a Nakajima, Erika |e investigator |4 oth | |
| 700 | 1 | |a Reinecke, Thomas |e investigator |4 oth | |
| 700 | 1 | |a Bowes, Cyndi |e investigator |4 oth | |
| 700 | 1 | |a Kirkpatrick, Grace E |e investigator |4 oth | |
| 700 | 1 | |a Thierauf, Julia C |e investigator |4 oth | |
| 700 | 1 | |a Reynolds, Kerri |e investigator |4 oth | |
| 700 | 1 | |a Willers, Henning |e investigator |4 oth | |
| 700 | 1 | |a Dighe, Anand S |e investigator |4 oth | |
| 700 | 1 | |a Saff, Rebecca |e investigator |4 oth | |
| 700 | 1 | |a Blumenthal, Kimberley |e investigator |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t Cancer cell |d 2002 |g 40(2022), 1 vom: 10. Jan., Seite 103-108.e2 |w (DE-627)NLM119589826 |x 1878-3686 |7 nnns |
| 773 | 1 | 8 | |g volume:40 |g year:2022 |g number:1 |g day:10 |g month:01 |g pages:103-108.e2 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.ccell.2021.12.002 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 40 |j 2022 |e 1 |b 10 |c 01 |h 103-108.e2 | ||